beqom Selected by JTI to Manage Global Compensation for 40,000 Employees
5.11.2019 09:00:00 EET | Business Wire | Press release
beqom, a cloud-based total compensation software provider, today announced it has been selected by Japan Tobacco International (JTI), an $11bn company that markets more than 100 brands, to manage Total Rewards for its 40,000+ employees across 80 countries.
The beqom solution will manage all aspects of compensation, including benchmarking and rewards analysis, base pay management, short-term incentives (bonus), long-term incentives, and sales performance management — all managed on beqom’s single platform.
The entire tobacco industry is going through a major change, and so is JTI. They are offering consumers a wider choice than ever before, through significant investments in reduced risk products, which has led to the need to manage their changing business with better, modern technologies. In beqom they found a modern, user friendly, attractive solution for their workforce that supports organizational agility and enables them to meet the different needs of mature and emerging markets.
“With beqom, JTI will have a holistic end-to-end solution to manage all rewards elements and activities in one digital space, eliminating the risks with floating papers and spreadsheets, and accessible on all devices,” says Emmanuel Frenck, beqom Head for Southern EMEA. “The solution will support individualized rewards with employee choice and provide the visibility and analysis needed to ensure pay fairness and cost-effective compensation allocation.”
beqom is unique as an HR compensation solution in that it is the only solution that allows all forms of compensation to be managed on a single platform.
-------
About beqom
Happiness is the best driver for success.
Our mission is to make the workforce of our customers happy. beqom drives happiness by allowing business managers to lead, align, and motivate employees and partners. beqom’s cloud-based total compensation platform is used globally across all industry sectors by over 100 large companies such as Microsoft and Vodafone. It addresses all performance and compensation aspects such as salary review, bonus, long-term incentives, commissions, benefits, non-cash rewards and all key drivers towards Employee Performance Management and Sales Performance Management. HR, sales, and finance leverage our platform to drive performance, retention, cost optimization, efficiency, compliance and… happiness among their people.
About JTI
JTI is a leading international tobacco and vaping company with operations in more than 130 countries. It is the global owner of both Winston, the number two cigarette brand in the world, and Camel, outside the USA and has the largest share in sales for both brands. Other global brands include Benson & Hedges, Natural American Spirit, Mevius and LD. JTI is also a major player in the international vaping market with its brand, Logic and tobacco vapor brand, Ploom. Headquartered in Geneva, Switzerland, JTI employs over 45,000 people and was awarded Global Top Employer for the fifth consecutive year. JTI is a member of the Japan Tobacco Group of Companies. For more information, visit www.jti.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005324/en/
Contact information
English: Katherine McCabe | +1 571 310 6897 | katherine.mccabe@beqom.com
French: Lucile Cottard - +41 79 457 6162 - lucile.cottard@beqom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 13:17:00 EEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 12:11:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechnology executive, bringing over two decades of therapeutic and diagnostic R&D experience within industry to Mosaic Therapeutics, with a track record spanning from IND through to NDA/BLA/MAA approval. Most recently he served at BioXcel Therapeutics as EVP, Head of Product Developme
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 10:00:00 EEST | Press release
The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights - equipping executives with the perspective needed to make confident, high-stakes decisions. “Through our work we increasingly s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
